Evaluation of the effectiveness of adjuvant chemotherapy for locally advanced gastric cancer in real clinical practice

Background. Current Russian recommendations for adjuvant therapy for patients with gastric cancer are supported by the results of clinical studies conducted among Asian patient population. Given the discrepancy in the overall survival (OS) of patients of different ethnic groups, we can assume the fundamentally distinctive features of the biology of their tumors. Objective. Evaluation of the long-term results of treatment of patients with locally advanced gastric cancer. Methods For a retrospective analysis, patients with a diagnosis of II - III stage gastric cancer who received treatment from 2009 to 2010 in the St. Petersburg City Clinical Oncology Dispensary were selected. All patients underwent radical surgical treatment (resection/gas-trectomy), followed by adjuvant chemotherapy (ACT) in PF mode (taking into account the standards at the time of treatment initiation) for 4 to 10 weeks. Results. The median survival of patients undergoing complex treatment was 26 months. The number of weeks (4-6) from the initiation of surgical treatment to the onset of ACT did not significantly affect OS. The number of cycles of ACT significantly increases the OS (more than 3 cycles). The degree of tumor differentiation did not significantly affect OS, and the colloid histological type can reliably be a factor in the poor prognosis. Conclusion. The results of a retrospective study among patients of the City Clinical Oncology Dispensary are comparable to those of key international studies and their meta-analyzes. Search for ways to improve results should be through the use of perioperative chemotherapy. Adjuvant therapy remains relevant for those patients in whom the first stage of treatment was surgical due to the complicated course of the disease or for other reasons.

locally advanced gastric cancer, overall survival, adjuvant chemotherapy